Skip to main content

Table 1 Patient characteristics

From: The proinsulin/insulin (PI/I) ratio is reduced by postprandial targeting therapy in type 2 diabetes mellitus: a small-scale clinical study

 

Mitiglinide

Glimepiride

n (M/F)

15 (10/5)

7 (6/1)

Age, years

58.5 ± 11.5

65.1 ± 7.5

BMI, kg/m2

24.8 ± 4.0

26.3 ± 6.2

SBP, mmHg

137 ± 17

132 ± 20

DBP, mmHg

80 ± 7

79 ± 11

Total cholesterol, mmol/L

5.38 ± 0.98

5.43 ± 1.08

(mg/dL)

(208 ± 38)

(210 ± 42)

Triglycerides, mmol/L

1.71 ± 1.14

1.89 ± 0.74

(mg/dL)

(152 ± 101)

(168 ± 66)

HDL-C, mmol/L

1.39 ± 0.38

1.37 ± 0.31

(mg/dL)

(54 ± 15)

(53 ± 12)

Fasting glucose, mmol/L

6.88 ± 1.27

8.16 ± 1.05

(mg/dL)

(124 ± 23)

(147 ± 19)

2-h postload glucose, mmol/L

9.11 ± 1.94

11.6 ± 1.77

(mg/dL)

(164 ± 35)

(209 ± 32)

HbA1c(NGSP),%

6.80 ± 0.54

7.60 ± 0.63

Fasting IRI, pmol/L

52.7 ± 53.4

49.3 ± 36.1

(ng/mL)

(7.6 ± 7.7)

(7.1 ± 5.2)

HOMA-R

2.55 ± 3.10

2.67 ± 2.09

ISI (Matsuda’s index)

7.73 ± 3.16

7.68 ± 4.69

Insulinogenic index

0.80 ± 0.61

0.42 ± 0.38

CPR, nmol/L

0.59 ± 0.30

0.57 ± 0.17

(ng/mL)

(1.79 ± 0.93)

(1.72 ± 0.51)

Proinsulin, pmol/L

4.29 ± 4.16

4.77 ± 4.04

PI/I ratio

0.10 ± 0.11

0.19 ± 0.26

  1. Data are means ± standard deviation.
  2. BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; HDL-C, high-density lipoprotein cholesterol; HbA1c, hemoglobin A1c; NGSP, National Glycohemoglobin Standardization Program; IRI, immunoreactive insulin; HOMA-IR, homeostasis model assessment of insulin resistance; ISI, insulin sensitivity index; CPR, C-peptide immunoreactivity; PI/I ratio, proinsulin/insulin ratio.